<SEC-DOCUMENT>0000950170-25-071966.txt : 20250515
<SEC-HEADER>0000950170-25-071966.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515070504
ACCESSION NUMBER:		0000950170-25-071966
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		25948640

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>caba-20250515.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-14T19:43:14.4052+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:caba="http://www.cabalettabio.com/20250515" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4334bde2-5a07-4184-822f-856619542410" name="dei:EntityCentralIndexKey" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9">0001759138</ix:nonNumeric><ix:nonNumeric id="F_f217424a-8ba4-468a-adab-a418f75dce26" name="dei:AmendmentFlag" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="caba-20250515.xsd"/></ix:references><ix:resources><xbrli:context id="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-15</xbrli:startDate><xbrli:endDate>2025-05-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f96ce6ab-becd-4b0f-a4e6-ec2a3eb3539e" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_d39ffd4b-5265-4c8d-bec5-3c95e7b86b0c" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 15, 2025</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="margin-left:216pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0079b54-f709-4e24-b283-abf47d042a7c" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:20%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:20%;box-sizing:content-box;"/>
      <td style="width:18%;box-sizing:content-box;"/>
      <td style="width:41%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6654b117-6e61-45f0-9704-10c6574a9513" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_59dd4446-544e-49a4-99f6-71609133f893" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39103</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b67bd1c7-724e-4a34-8495-36f1255b860c" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-1685768</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e915322e-c07a-4ec4-863d-f8f09e691285" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2929 Arch Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bc424475-09fd-4c7e-9f8b-cef2d240357e" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 600</span></ix:nonNumeric></span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_813c40dd-3673-4b2f-af85-cafb8a5bee40" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Philadelphia</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_7ca040f3-1a04-4d9b-9627-fe5c57d0fc69" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pennsylvania</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_20ef0780-8a01-4140-9644-5c29df168338" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19104</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_557a62f6-3fe9-45c5-8cef-62030c89d01a" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(267)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_99618827-b291-4131-81ce-3b8b62c1f28b" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">759-3100</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5bd2d8ff-58ce-4e71-aa51-c792473457c3" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not Applicable</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a763dbc9-0edf-4952-8869-8617296ed97f" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60a0040a-28cd-41e6-bb7d-050cd25e0890" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08f79430-9e0d-4c65-b724-0022751f891d" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6847b76f-abf4-4109-a4a5-534827b18d5b" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:38%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:45%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4afca232-0a36-4148-87a2-dba156fe5838" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d3187903-6909-4115-a6a7-c2ff81fd46e0" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CABA</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a6813413-9acc-479f-a6c3-c376420a578e" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_a6bc969c-4910-407e-90f6-7008ab3f56c9" contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><h2 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2025, Cabaletta Bio, Inc. (&#8220;Cabaletta&#8221; or the &#8220;Company&#8221;) disclosed that its cash and cash equivalents as of March 31, 2025 was $131.8 million, compared to $164.0 million as of December 31, 2024. The Company expects that this cash position as of March 31, 2025 will enable it to fund its operating plan into the first half of 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in Item 2.02 of this Form 8-K does not present all information necessary for an understanding of the Company&#8217;s financial condition as of March 31, 2025 and is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item&#8201;7.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation FD Disclosure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2025, the Company posted to the &#8220;Investors &amp; Media&#8221; section of the Company&#8217;s website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.cabalettabio.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an updated corporate presentation (the &#8220;Corporate Presentation&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2025, the Company issued a Press Release entitled &#8220;Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts&#8221; (the &#8220;Press Release&#8221;). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:3.8%;box-sizing:content-box;"/>
      <td style="width:2.94%;box-sizing:content-box;"/>
      <td style="width:93.26%;box-sizing:content-box;"/>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="caba-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by the registrant on May 15, 2025, furnished herewith.</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document).</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:49.72%;box-sizing:content-box;"/>
      <td style="width:1.74%;box-sizing:content-box;"/>
      <td style="width:5%;box-sizing:content-box;"/>
      <td style="width:43.54%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 15, 2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>caba-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><img src="img132663336_0.jpg" alt="img132663336_0.jpg" style="width:272px;height:37px;"><font style="color:#000000;white-space:pre-wrap;font-size:17.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:17.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">TM </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">trial &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Multiple Phase 1/2 disease cohorts fully enrolled across the RESET&#153; clinical development program; 44 patients enrolled and 23 patients dosed as of May 9, 2025 &#x2013;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; SLE and LN registrational discussions with FDA anticipated in 3Q25; systemic sclerosis registrational discussions with FDA anticipated in 4Q25 &#x2013;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; New clinical data on rese-cel in myositis, SLE / LN and systemic sclerosis to be presented in three oral sessions at the EULAR 2025 Congress in June &#x2013;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">PHILADELPHIA, May 15, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced plans for an anticipated 2027 rese-cel BLA submission following a recent U.S. Food and Drug Administration (FDA) meeting on a proposed registrational cohort design for the RESET-Myositis trial of rese-cel (resecabtagene autoleucel, formerly known as CABA-201).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Myositis is a severe, disabling, and potentially life-threatening multi-system disease that affects approximately 80,000 patients in the U.S. with a three-fold increased mortality risk primarily due to interstitial lung disease, cardiovascular disease and an increased risk of cancer. Chronic, monthly IVIg infusion is the only FDA-approved treatment option for a subset of these patients,&#x201d; said David J. Chang, M.D., Chief Medical Officer of Cabaletta. &#x201c;The clinical safety and efficacy data evaluating a single, weight-based dose of rese-cel after discontinuation of all immunosuppressants in the RESET-Myositis trial and data from the broader RESET clinical program supported the recent discussions with FDA and RMAT designation for rese-cel in myositis. Based on the minutes from our recent FDA meeting, we are proceeding with a registrational study design that includes two independent, subtype specific cohorts, each with approximately 15 patients and a primary endpoint within 26 weeks of rese-cel infusion. The primary endpoint incorporates a validated clinical improvement score used in the approval of IVIg for patients with dermatomyositis. The clinical data that supported the FDA discussions will be presented in three oral sessions at the upcoming EULAR congress while correlative basic science data is being presented at the ongoing ASGCT conference. With the completion of enrollment in the Phase 1/2 RESET-Myositis trial and the ability to leverage our industry-leading</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">U.S. clinical trial network, we look forward to expanding our ongoing clinical study and submitting our first BLA for rese-cel.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Regulatory and Manufacturing Updates</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Following a Type C meeting with the FDA and receipt of meeting minutes in April 2025, Cabaletta is planning to implement the following design for two single-arm, disease-specific registrational cohorts in the ongoing RESET-Myositis trial, either of which, if successful, enable a future Biologics License Application (BLA) submission for rese-cel in myositis:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">One cohort will evaluate approximately 15 patients with either dermatomyositis (DM) or antisynthetase syndrome (ASyS) and one cohort will evaluate approximately 15 patients with immune-mediated necrotizing myopathy (IMNM). Inclusion and exclusion criteria will remain highly similar to the Phase 1/2 cohorts. While a BLA for either cohort can be submitted independently, we believe that together, these two cohorts have the potential to support a broad label to address many of the approximately 80,000 myositis patients in the U.S., including those with or without a history of IVIg use. </font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The registrational cohorts will evaluate the same single, weight-based infusion of rese-cel at 1 x 10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> cells/kg as used in the Phase 1/2 myositis cohorts. The primary endpoint for the registrational cohorts is based on the total improvement score (TIS) to evaluate patient outcomes within 26 weeks of rese-cel infusion.</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The FDA supported the use of pooled rese-cel safety data from across the entire RESET clinical trial program to supplement myositis specific safety data for the BLA submission in myositis. In the recent Type C meeting, Cabaletta aligned with the FDA on the size of the required safety database, which is expected to be approximately 100 autoimmune disease patients treated with the same single weight-based dose, over 40% of which have already been enrolled across the RESET clinical development program.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) designation to rese-cel for the treatment of myositis. The advantages of RMAT designation include all the benefits of Fast Track and Breakthrough Therapy Designation programs, including potential for expedited review of the BLA submission, and provide opportunities for more frequent interactions with the FDA with the goal of facilitating drug development. New clinical data from each of the RESET-Myositis, RESET-SLE&#153; and RESET-SSc&#153; trials will be presented in three oral presentations at the upcoming EULAR 2025 Congress from June 11-14, 2025, in Barcelona, Spain.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta also continues to make timely and disciplined investments in its manufacturing strategy, which is designed to reduce the cost of goods sold, increase scale and shorten the vein-to-vein time. To support commercial supply readiness, Cabaletta has been advancing BLA-enabling activities for our lentiviral vector process at Oxford Biomedica and implementing the planned commercial drug product process at Lonza, which is expected to come online in early 3Q25 to support registrational enrollment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Financial Updates</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had cash and cash equivalents of $131.8 million, per our Form 10-Q being filed this morning, compared to $164.0 million as of December 31, 2024. The</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Company expects that its cash and cash equivalents as of March 31, 2025, will enable it to fund its operating plan into the first half of 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About myositis</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Myositis refers to a group of severe, disabling and potentially life-threatening autoimmune diseases characterized by severe inflammation and muscle weakness. It commonly impacts women of middle age, and patients can experience weakness, fatigue, pain, shortness of breath and difficulty swallowing in addition to symptoms in other organ systems, such as the lung, heart or skin. The risk of mortality is approximately 3 times higher than the general population, primarily due to interstitial lung disease, or ILD, cardiovascular disease and/or malignancy. Myositis is classified into several subtypes based on the underlying immune mechanisms and clinical characteristics, including dermatomyositis, or DM, antisynthetase syndrome, or ASyS, and immune-mediated necrotizing myopathy, or IMNM. These subtypes affect approximately 80,000 patients in the U.S. and approximately 85,000 patients in Europe. Current standard of care typically involves medications to suppress the immune system and/or chronic intensive therapies such as monthly infusions of intravenous immunoglobulin, or IVIg, which is the only FDA approved therapy for adult DM patients. Despite these therapies, many myositis patients have disease that remains refractory to existing medications. Based on quantitative market research with myositis treating physicians, we believe approximately 20% to 25% of the 80,000 patients in the US with myositis, representing those with refractory moderate or severe disease, would be potential candidates for treatment with rese-cel.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About rese-cel (formerly referred to as CABA-201)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Rese-cel is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease. Following a one-time infusion of a weight-based dose, rese-cel is designed to transiently and deeply deplete all CD19-positive cells in both the peripheral circulation and within tissues. We believe this approach has the potential to reset the immune system and result in profound clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating rese-cel in the RESET&#153; (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across expanding portfolios of autoimmune diseases in a broad range of therapeutic areas, including rheumatology, neurology and dermatology.</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About Cabaletta Bio</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA&#153; platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET&#153; (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio&#x2019;s headquarters and labs are located in Philadelphia, PA. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">www.cabalettabio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and connect with us on LinkedIn.</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta&#x2019;s business plans and objectives as a whole; Cabaletta&#x2019;s ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta&#x2019;s ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta&#x2019;s clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support rese-cel&#x2019;s safety and activity profile; statements regarding the timing of interactions with regulatory authorities, including such authorities&#x2019; review of safety information from Cabaletta&#x2019;s ongoing clinical trials and potential registrational pathway for rese-cel; Cabaletta&#x2019;s ability to leverage its  emerging clinical data and its efficient development strategy; Cabaletta&#x2019;s ability to capitalize on and potential benefits resulting from its research and translational insights; including those related to any similarly-designed constructs or dosing regimens; Cabaletta&#x2019;s expectation regarding the clinical data to be presented at the upcoming EULAR congress; Cabaletta&#x2019;s expectations around the potential success and therapeutic benefits of rese-cel; the Company&#x2019;s advancement of separate Phase 1/2 clinical trials of rese-cel in patients with SLE, myositis, SSc and gMG and advancement of the RESET-PV and RESET-MS trials, including updates related to status, safety data, efficiency of clinical trial design and timing of data read-outs or otherwise; Cabaletta&#x2019;s ability to expand its clinical supply for registrational trial(s) across the RESET clinical development program as well as to expand its manufacturing options for rese-cel; Cabaletta&#x2019;s ability to leverage its existing industry-leading U.S. clinical trial network to initiate enrollment in the myositis registrational cohorts in the second half of 2025 and accelerate development of its therapy for patients and to generate clinical and translational data;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta&#x2019;s expectations surrounding the RMAT designation and the anticipated initiation of new registrational cohorts and potential BLA submission; Cabaletta&#x2019;s belief regarding alignment with FDA on registrational trial design; and Cabaletta&#x2019;s use of capital, expense and other financial results in the future and its ability to fund operations into the first half of 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to regulatory filings and potential clearance; the risk that signs of biologic activity or persistence may not inform long-term results; Cabaletta&#x2019;s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of rese-cel; the risk that the results observed with the similarly-designed construct employed in academic publications, including due to the dosing regimen, are not indicative of the results we seek to achieve with rese-cel; risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabaletta&#x2019;s ability to retain and recognize the intended incentives conferred by Regenerative Medicine Advanced Therapy, Orphan Drug Designation and Fast Track Designation or other designations for its product candidates, as applicable; risks related to Cabaletta&#x2019;s ability to protect and maintain its intellectual property position; risks</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">related to fostering and maintaining successful relationships with Cabaletta&#x2019;s collaboration and manufacturing partners; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Cabaletta&#x2019;s product candidates will not be successfully developed and/or commercialized; the risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the Company&#x2019;s ability to fund its operations and continue as a going concern. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta&#x2019;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#x201c;Risk Factors&#x201d; in Cabaletta&#x2019;s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta&#x2019;s other subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Contacts:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Anup Marda</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">investors@cabalettabio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img132663336_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132663336_0.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /TV\:>-
M-&^'WAF_U_7[^+3=*LH_,FN)3PH[ #J23@ #DDU\?Q?M4?&K]H#4+@?!CP1;
MZ?X:CD,:Z_KG_+3!Z@$[1[@!\>M-_:HBO/VA/VH/!'P52XE@\-V<']L:T(F(
MWC!(!^BA5'H9J^S/#OAW3O"NCVFE:59PV-A:Q+%#;PH%5% P  *QUD[+8]1*
MGA:<92CS2EKKLD?'UUXD_;!\ Q_VGJ&E>&_&5I&"TME9@"7:.N,",DXZ8S]#
M7L7[.O[5?A_X^1W6G&UF\.^+M/R+[0KT_O8\'!920-R@\'@$'J.A/N+ ,,'F
MO)/$'[,_A'6OBYIGQ(@6XTKQ-9XW36$AC6X XQ(HX;(.TY[?2GRRB[IF;K4J
MT6IPL^C1ZW17S5^TC^U?<_#GQ)9^ O FCGQ3\0;Y05M%R4M@1P7QWQSC@ =:
M\^\O]LJWLO[7;4/#L^!YATD0Q;R.NS.SK^/XT.HNA,<'.45*32OM<^UJ^=/V
MI/CMXE^$?CKX6:3H7V7[+XDU=;*]^T1;V\LR1+\ISP<.:?\ LT_M6#XN:E?^
M$?%6E-X7\?Z9G[3ILF0LH'!>//IW'OFO)O\ @HOKEMX7\;?!76+TE;/3]9:Z
MF*C)V))"S8'T!I2E[O,C;#X:2Q'LIKO^1]P(VY0:6OB#2_C5^T3^T1)+JGPR
MTG3_  AX2#%;6]U:-7>Y4<;OF4_H!2_\-&_&[]G77+-?C/H]KK?A6ZE$3:YI
M,:J("3U.T ?@1^-'M$2\#/:ZOVOJ?;])6=X?\06'BC1;/5M,N4N["\B6:&:,
MY5U(R"*^9?CM^UEKUKX\/PW^$NBKXF\9+Q=W##=!9^H/;([YXJY245<Y:="=
M67+%;'U71WKXGNIOVQO"]G_;,]UX?U^*(>9)I,,$0D9>I4$(#GZ&O9_V:/VG
M=.^/>FWEI<V;:%XLTL^7J&DS'YD;IN7/.W/Y4E-/0UJ86<(\\6FEV,GXO?''
MQ)X+_:8^&G@73C:_V)X@B=[SS8MTF06 VMGCH*^A@>!7QM^T7_R?)\#_ /KA
M+_Z$]?3GQ2^)NB?"'P7?^)=>N!!8VB9P/O2-V11W)-*+U;8ZM.\:2@M6OU.N
MHKX9TWXI?M-?M""36? MAI_@KPK(3]EDU%%,DZ9X;+*3^6!5RQ_:0^,W[/>O
M6=M\;-%M]5\,W4@B'B#2D $)/ W;0!CZC/O1[1=C3ZC/923?:^I]<_$+7+CP
MSX'UW5;3:;JRLY9XO,&5W*I(R/3BO./V1_BWK?QL^#-AXH\0K;+J4UQ+&PM8
MRB84@#@DUU/Q,UBTU_X*^(M1L)TN;.ZTF:6&:,Y5U,9((KXC_8ON_CW'\.="
M3PA;Z*_@C[<WF/=,//V[AYG;\JER:FBJ6'4\/.3LFGU/I']H_P"/'B3X5_%+
MX9^']&6S:Q\0WOV>\-Q$78+N ^4Y&#S7T2IRH-?"W_!0AM93XH?"!O#ZQ-K@
MNW^QK<?<,NX;=WMFO=?@CKGQ>TV'7+WXP#1K'3;: 2V\U@PPN.6+' XQ34O>
M:85<.O84ZD;7_%ZGNM&:^)=0_:<^+O[0'BB^T[X'Z-;6/AZQE,3^(M40,DK
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MOB;^U5X@^*'@?5_#6J? _P 026U_ T670'8Q'RL..H.#7KGP9_;@^'7CKP[
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2]M&(XXU'95 P!]*M444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>caba-20250515.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-14T19:43:14.6816+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.cabalettabio.com/20250515" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:caba="http://www.cabalettabio.com/20250515" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="caba-20250515.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 15,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *$XKUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *$XKUKOG>U)[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M8WAJ^VJ2IP=/UK6#+B[4U%]IU2HH[NL+"0L4QC;]9W@RE6!Q+0^NTLAS\B,
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M2P$"% ,4    " "A.*]:[YWM2>X    K @  $0              @ '#
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "A.*]:F5R<(Q &  "<)P
M$P              @ '@ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( *$XKUJ4'C);F@0  /(1   8              " @2$(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "A.*]:GZ ;\+$"  #B#
M#0              @ 'Q#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *$X
MKUJ7BKL<P    !,"   +              "  <T/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( *$XKUHZJJ+G0 $  #P"   /              "  ;80  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "A.*]:)!Z;HJT   #X 0  &@
M            @ $C$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "A.*]:99!YDAD!  #/ P  $P              @ $($P  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !2%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="caba-20250515.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="caba-20250515.htm">caba-20250515.htm</File>
    <File>caba-20250515.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "caba-20250515.htm": {
   "nsprefix": "caba",
   "nsuri": "http://www.cabalettabio.com/20250515",
   "dts": {
    "inline": {
     "local": [
      "caba-20250515.htm"
     ]
    },
    "schema": {
     "local": [
      "caba-20250515.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20250515.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20250515.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cabalettabio.com/20250515/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-071966-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-071966-xbrl.zip
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M6V=KX)$:N[I+.E_.B&%J#:AXHS/4$75/HV7G5="RHS%-LS1&#0^/0M*%0X/
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M?X;7<OD&&WYG\EK7Z[>G$[[C3+:#9I#R\:>?#IJ]HA]_^G]02P,$%     @
MH3BO6L\W!8/%"   JF4  !$   !C86)A+3(P,C4P-3$U+GAS9.U=6W.C-AA]
M[Z]0W9?=Z6+ 2;:-9YV.F^QV/,UN,G%VVFFGLX-!=C3%DBM$XOS[2H"X66!B
M![ ]SDL(?#K?.>B".):<#[\LYRYXA-1#! \Z9M?H (AMXB \&W2^CK7A^'(T
MZOQR\=V'[S4-7'T:?0%?X!,8V@P]PBODV2[Q? K!F_'GM^#/7^^NP=A^@',+
M7!';GT/,@ 8>&%OT=?WIZ:GK3!'VB.LSGL[KVF2N TV+P"\IM,1Y<&4Q"/H]
MHW>F&6>:>7IOGO=/3_KF:??]S^;['PVC;QBI8F3Q3-'L@8$W]EL@2O'<&$/7
MA<_@$\(6MI'E@K',^@Z,L-T%0]<%=Z*8!^Z@!^DC=+HAZ-)S^EXH@EET!MD7
M:PZ]A67#02<EQ;8FE@L9LR:(!$I$:N/,/.L BS&*)CZ#GPB=7\&IY;MLT/'Q
M?[[EHBF"#K_)+A1W)Q.0NLQK!7M]B/UY+TZZG%"W2^A,)#)TN&00>VCB0DV$
M01K<.T_KB2H,BPN&52F');CT3(&GDRBA8>I_?KX.JU8&NPC_FXE.$31.='%Y
M8GE0AON>-K.L15QB:GF3(#JZ(,B<RF 'HJQN#]K=&7G4^85,H+CH,-4],L[T
M\&(Z%)40YBV3\<82$UZN"(QNAWE^?JX'5SL7WP$0-!@T7Q#*0-ANKHD=U$9)
M,O&7)C-JXI1F]K03L\O!.@ K6UP!77T[$K*>-B(15_*F)&0EB>QG17F5M5HI
MHU?4?L2!)@Y*<ZZTNI<E539Q';K,DV=**:A[2$+!PIBP(*\X)4\N%@A/27B&
MGQ,UU*?$A??/"PC$P=>[4;5106?6DF R?]9%,5V.Z/+W$#L?,4/L><3ST7E
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M_LWC3?2O'8CO T!U4P'@P#MSZ#H+P!I$KD)/APGA; 9<0. =EIP)MQX@WY'
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M<H=R_L,Y78X5W6Y<4>,'U#1295;_Z8.5IT\; TIQP$X:8RC 7,-KF-).U8C
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MNV&R_?!H_)\Z\B>'KPH[!FF(&@AH9KE! NET'U<HVQ82:I&VW NT""MO,)T
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MZ!&PI["6#/M=4MD(?;CH.K#%AMPZ*+#)MHM,N"!]VD2JS39;@D \N/KH0!%
MU=A[(40RW^)EOW)K;6.7,/":Q1783<=WR^-EZ19*<2 8.'1X^*_8<1I_8Q0U
M!&S#)WB2R0<<XX8EN:?I.]Y<EZU@2+8V4113Q>%/K['P;4($Y)U; S:DG+8N
M-+3>)2!#T359150(%.P>Y:J >MXL5W57\RN8N81[;!QQ.H>Z&S^>LRF5F\SW
M$ 1<J_C\?CNB!@?;;T&YU?2+$V3MK/Z\W]NPS;)^/BR;"GLKY/S>Q2GNQP&Y
M+\;LND'YK\:\]Z?UQWK:79XT:*]__&$)MK<N@;=&_'TUXI\]'NE\\?POSQY/
MZT(]_W]02P$"% ,4    " "A.*]:C]O_#1H6  #FS0  $0
M@ $     8V%B82TR,#(U,#4Q-2YH=&U02P$"% ,4    " "A.*]:SS<%@\4(
M  "J90  $0              @ %)%@  8V%B82TR,#(U,#4Q-2YX<V102P$"
M% ,4    " "A.*]:GJ[^T\H:  "MDP  #P              @ $]'P  8V%B
B82UE>#DY7S$N:'1M4$L%!@     #  , NP   #0Z      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>caba-20250515_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="caba-20250515.xsd" xlink:type="simple"/>
    <context id="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_4334bde2-5a07-4184-822f-856619542410">0001759138</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_f217424a-8ba4-468a-adab-a418f75dce26">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_f96ce6ab-becd-4b0f-a4e6-ec2a3eb3539e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_d39ffd4b-5265-4c8d-bec5-3c95e7b86b0c">2025-05-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_e0079b54-f709-4e24-b283-abf47d042a7c">CABALETTA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_6654b117-6e61-45f0-9704-10c6574a9513">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_59dd4446-544e-49a4-99f6-71609133f893">001-39103</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_b67bd1c7-724e-4a34-8495-36f1255b860c">82-1685768</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_e915322e-c07a-4ec4-863d-f8f09e691285">2929 Arch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_bc424475-09fd-4c7e-9f8b-cef2d240357e">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_813c40dd-3673-4b2f-af85-cafb8a5bee40">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_7ca040f3-1a04-4d9b-9627-fe5c57d0fc69">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_20ef0780-8a01-4140-9644-5c29df168338">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_557a62f6-3fe9-45c5-8cef-62030c89d01a">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_99618827-b291-4131-81ce-3b8b62c1f28b">759-3100</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_5bd2d8ff-58ce-4e71-aa51-c792473457c3">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_a763dbc9-0edf-4952-8869-8617296ed97f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_60a0040a-28cd-41e6-bb7d-050cd25e0890">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_08f79430-9e0d-4c65-b724-0022751f891d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_6847b76f-abf4-4109-a4a5-534827b18d5b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_4afca232-0a36-4148-87a2-dba156fe5838">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_d3187903-6909-4115-a6a7-c2ff81fd46e0">CABA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_a6813413-9acc-479f-a6c3-c376420a578e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1ba74a69-5567-41c0-a8b2-360ebc03c6a9"
      id="F_a6bc969c-4910-407e-90f6-7008ab3f56c9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
